NEW YORK (GenomeWeb News) — Illumina has sold 1,000 of its HumanHap550 BeadChips to GlaxoSmithKline, Illumina said today.
 
Under the agreement, GSK will use Illumina’s services and hardware at a “third party facility” in what Illumina said is a continuation and expansion of an existing genotyping arrangements between the two companies.
 
The firms have had running genotyping agreements for more than five years.
 
Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.